Modified Welsh regimen: a promising therapy for actinomycetoma
Damle, D.K.; Mahajan, P.M.; Pradhan, S.N.; Belgaumkar, V.A.; Gosavi, A.P.; Tolat, S.N.; Gokhale, N.R.; Mhaske, C.B.
Journal of Drugs in Dermatology Jdd 7(9): 853-856
2008
ISSN/ISBN: 1545-9616 PMID: 19112799 Document Number: 616354
Mycetoma has a worldwide geographical distribution which is extremely uneven; however, it is a common disease in India and responsible for causing significant morbidity. Treatment of this condition is often a challenge for the treating dermatologist. The authors report a promising therapy for patients of actinomycotic mycetoma. This assessment series included 18 patients with a confirmed diagnosis of actinomycetoma, and who had shown a poor response to previous treatments. Patient received a combination therapy of the Welsh regimen (amikacin along with cotrimoxazole) to which rifampicin was added as a third drug. Clinical evaluation included radiology and laboratory investigations. Sixteen patients out of 18 completed the combination therapy, which lead to remission. Two patients were lost to follow-up. Of the 16 patients in remission, no recurrence was observed during a follow-up period of up to 18 months.
Document emailed within 1 workday
